$24.81
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
Overview
52-week range
$15
$44
34% of range
Avg surprise (last 3)
-2.7%
Avg reaction (last 2)
-1.2%
50% positive
Latest IV / EM
85%
EM ±19.5% · $25 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.49 | $-0.56 | +12.5% | -145.0% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.02 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $0.15 | $-0.51 | +129.4% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.20 | $-0.08 | -150.0% | — | -3.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.08 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.31 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.09 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.26 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.70 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | AMC | -$0.44 | $0.15 | -393.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84M | — | $83M | $86M | $88M | — | $86M | $87M |
| Cost of revenue | $21M | — | $19M | $18M | $16M | — | $16M | $15M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-18M | — | $-7M | $-4M | $-28M | — | $5M | $5M |
| Net income | $-15M | — | $-501,000 | $5M | $-26M | — | $2M | $9M |
| EPS (diluted) | $-0.49 | — | $-0.02 | $0.15 | $-0.90 | — | $0.08 | $0.31 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $64M | $117M | $86M | $82M | $90M | $120M | $95M | $86M |
| Inventory | $10M | $10M | $9M | $8M | $7M | $8M | $7M | $8M |
| Total current assets | $329M | $361M | $358M | $349M | $349M | $360M | $345M | $320M |
| Total assets | $548M | $579M | $563M | $545M | $502M | $531M | $515M | $487M |
| Long-term debt | $8M | $10M | $10M | $8M | $9M | $10M | $10M | $10M |
| Total liabilities | $86M | $108M | $96M | $89M | $61M | $75M | $74M | $63M |
| Total equity | $461M | $471M | $467M | $455M | $440M | $456M | $441M | $424M |